Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments

As a catalytic subunit of the positive transcription elongation factor b (P-TEFb), cyclin-dependent kinase 9 (CDK9) has been demonstrated to contribute to carcinogenesis. This review focuses on the development of selective CDK9 inhibitors and proteolysis-targeting chimera (PROTAC) degraders. Twenty...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Lanshu, Liu, Yi, Chen, Hui, Shen, Lisong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243401/
https://www.ncbi.nlm.nih.gov/pubmed/37272701
http://dx.doi.org/10.1080/15384047.2023.2219470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243401/
https://www.ncbi.nlm.nih.gov/pubmed/37272701
http://dx.doi.org/10.1080/15384047.2023.2219470

Ejemplares similares